secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIMEDX GROUP, INC. (MDXG)
CIK:        0001376339
Form:       8-K
Filed at:   2022-11-02T23:59:59+00:00
Accession:  0001193125-22-275856
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiMedx Q3 net sales $67.7M (+7.3% YoY); net loss widens to $8.4M; launches two surgical products
--------------------------------------------------------------------------------

- Net sales $67.7M, up 7.3% YoY; net loss $8.4M vs $2.3M loss prior year; adjusted EBITDA loss $0.7M vs gain $7.0M.
- Launched AXIOFILL and AMNIOEFFECT for surgical recovery; obtained Japan reimbursement for EPIFIX.
- Appointed Todd Newton interim CEO; new segment reporting for Wound & Surgical and Regenerative Medicine.
- Advanced KOA registrational study with FDA, including Type B RMAT meeting and CMC filings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1376339/000119312522275856/0001193125-22-275856-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1376339/000119312522275856/d399649d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-275856

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer